dm+d

109033004

Lactation Safety Information

For breast cancer

For breast cancer
Low levels anticipated in milk due to the drug's properties
May interfere with lactation
Very limited published evidence of safety
24 September 2020

New Medicines

Xyosted Hypogonadism

Information

Xyosted
New formulation
Antares Pharma
Antares Pharma

Development and Regulatory status

None
None
Approved (Licensed)
Nov 19No further development reported. Company has no UK presence so assume no plans for UK launch.
Oct 18Approved in the US for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, e.g. primary hypogonadism, hypogonadotropic hypogonadism. The company plans to launch with a monthly list price of $400-500 which is less than AndroGel´s list price of $625 [1].

Category

Testosterone replacement therapy administered subcutaneously [1]
The crude incidence rate of symptomatic androgen deficiency was 12.3% per 1000 person-years and increased with age: 5.9%, 11.2%, and 23.3% per 1000 person-years in men who were in their 40s, 50s, and 60s, respectively, at baseline.
Hypogonadism
Subcutaneous injection